Loading
Life sciences · Journal article
Expert Opinion on Drug Delivery · August 23, 2026
Raises a question worth testing. It does not answer one.
This is an expert opinion review examining design bottlenecks and emerging architectures in coated and dissolving microneedle technology for drug and vaccine delivery. The authors propose that high-density coated microneedles with mechanical applicators, tip-loaded designs, and detachable architectures may address clinical translation challenges, and highlight micro-dose vaccines as a near-term application. No clinical evidence, trial data, or FDA approvals are reported; the article frames these approaches as theoretical solutions and identifies gaps requiring further development.
Journal article.
No FDA-approved coated or dissolving microneedles for therapeutics or vaccines currently exist Critical design challenges identified include skin elastic recoil, needle bouncing-out, skin penetration, tissue hydration variation, and micro-channel patency High-density coated microneedles paired with mechanical applicators proposed to circumvent skin penetration challenges
No quantitative efficacy or safety data provided; all proposals are theoretical or based on mechanistic reasoning. No specific dose, pharmacokinetic, immunogenicity, or clinical outcome data presented.
This review does not report clinical trial data and should be read as a survey of design principles and unproven concepts. Readers should understand that no marketed or approved microneedle products for systemic drug or vaccine delivery currently exist, and proposed solutions remain in preclinical or early development phases.
This is a narrative review article analyzing design challenges and proposing theoretical solutions for microneedle technology, without reporting original experimental data, clinical trials, or comparative evidence.
This review does not report clinical trial data and should be read as a survey of design principles and unproven concepts. Readers should understand that no marketed or approved microneedle products for systemic drug or vaccine delivery currently exist, and proposed solutions remain in preclinical or early development phases.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Despite decades of research, no FDA-approved coated or dissolving microneedles currently exist for therapeutics or vaccines. Clinical translation requires aligning biophysical delivery mechanisms with product-specific regulatory and biopharmaceutical standards. AREA COVERED: This review analyzes critical design bottlenecks, including the skin's elastic recoil, the needle bouncing-out challenge, skin penetration, variation of tissue hydration, and prolonged micro-channel patency. We examine progress in high-density coated and tip-loaded microneedles paired with mechanical applicators, alongside needle-detachable designs that decouple drug delivery from needle dissolution. We highlight the necessity of targeting micro-dose payloads, such as hormones and vaccines, to overcome the inherent geometric volume limitations of microneedles. EXPERT OPINION: Bridging microneedle designs with clinical applications and regulatory requirements is essential. High-density coated microneedles provide more surface area to accommodate fast dissolution of the thin payload coating and, when paired with an applicator, can circumvent the skin penetration challenges. Loading drug at the tips of dissolving microneedles offers fast dissolution due to deep tip penetration, while detachable architectures, particularly active fluid-triggered systems, offer solutions to the variabilities of skin hydration and elastic recoil. Micro-dose vaccines represent a promising near-term application; their threshold-based immunology accommodates the limited volumetric capacity of microneedles while enabling dose sparing.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.